Sydney Empax clinic opens, extending Emyria’s national reach to four states
Emyria Limited (ASX: EMD) has opened its Sydney Empax clinic at Matilda Nepean Private Hospital in Kingswood, Western Sydney, with first patients having commenced treatment. The opening extends the company’s clinical presence across four states: New South Wales, Victoria, Queensland, and Western Australia.
The clinic opened on schedule, consistent with the April 2026 ASX announcement, and adds 4 treatment beds to the national network. Total bed capacity has grown from 14 to 18, supporting up to 90 dosing sessions per week nationally.
When big ASX news breaks, our subscribers know first
What the Sydney opening means for Emyria’s national platform
The clinic commenced operations with trained clinicians and Authorised Prescribers already in place, making it treatment-ready from day one rather than simply open.
Significantly, first patients have been approved for treatment under the New South Wales workers’ compensation scheme. This provides evidence of a growing reimbursement pathway and supports Emyria’s objective of integrating evidence-based mental health therapies into payer-supported healthcare settings.
The national platform now spans four operational pillars:
- Patient access
- Workforce development
- Treatment delivery
- Real-world evidence generation
The capacity to generate real-world evidence from regulated clinical settings carries strategic weight beyond day-to-day treatment delivery. Data collected across 18 treatment beds and up to 90 dosing sessions per week is expected to strengthen the evidence base for integrating these therapies into mainstream healthcare and payer systems.
Greg Hutchinson, Executive Chair
“The opening of our Sydney clinic establishes Emyria across Australia’s four most populous states and adds further specialist clinical infrastructure to support the delivery of these treatments at scale. With trained clinicians, Authorised Prescribers, treatment capacity and approved patients now in place, our focus is on converting this platform into improved patient outcomes, increased treatment volumes and high-quality real-world evidence.”
Understanding psychedelic-assisted therapy and why it matters
Psychedelic-assisted therapy involves psychiatrist-led treatment programs in which regulated substances, such as MDMA (for post-traumatic stress disorder) and psilocybin (for treatment-resistant depression), are administered within supervised, hospital-integrated settings. These are not conventional therapy sessions. They are delivered with specialist psychiatric oversight inside regulated clinical environments, which distinguishes them meaningfully from standard outpatient mental health care.
The scale of the underlying healthcare need provides important context. Mental health and substance use disorders accounted for 15% of Australia’s total disease burden in 2024, according to the Australian Institute of Health and Welfare. The latest ABS National Study of Mental Health and Wellbeing found approximately 4.3 million Australians aged 16 to 85 experienced a mental disorder within a 12-month period.
Real-world evidence collected from regulated clinical settings matters because it builds the data foundation needed to support broader integration of these therapies into established healthcare and reimbursement systems, extending their reach beyond clinical trials into standard care pathways.
Australian platform building toward U.S. opportunity
Emyria’s Australian operations are generating practical experience in clinical governance, therapist training, patient screening, treatment delivery, and payer-supported access. This operating experience is directly informing the company’s assessment of opportunities to apply its model in the United States.
The Empax Global Partnership Program, launched in April 2026, adds a capital-light sponsor-funded revenue stream alongside patient treatment, with North American partner Psyence Group already engaged to support a Phase IIb trial in Adjustment Disorder patients with advanced cancer.
Two recent developments have reinforced the U.S. strategic direction. Emyria was selected to present at the U.S. Food and Drug Administration’s public hearing on the potential future therapeutic use of psychedelic drugs (16 September 2026 ASX announcement). The company also appointed former U.S. Secretary of Veterans Affairs Dr. David Shulkin as Strategic Advisor (21 September 2026 ASX announcement).
For readers interested in what Emyria presented to U.S. regulators and how its Australian clinical data was received, our detailed coverage of Emyria’s FDA hearing appearance examines the four implementation areas the hearing addressed and where Emyria’s existing operational infrastructure maps against each.
The company’s stated near-term focus is on converting the national platform into improved patient outcomes, increased treatment volumes, and high-quality real-world evidence.
The table below summarises Emyria’s current national clinic footprint:
| State | Location | Treatment Beds |
|---|---|---|
| New South Wales | Matilda Nepean Private Hospital, Kingswood (Western Sydney) | 4 |
| Victoria | Empax clinic (operational) | – |
| Queensland | Empax clinic (operational) | – |
| Western Australia | Empax clinic (operational) | – |
| Total | 18 |
Note: The ASX announcement confirms a total of 18 national treatment beds following the Sydney opening but does not disclose individual bed counts for the Victoria, Queensland, and Western Australia clinics.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market. Click the “Free Alerts” button at StockWire X to get the next market-moving healthcare announcement the moment it drops.